Welcome toGeniouskin
About Us
Geniouskin creates a living skin substitute using the patient’s own cells.
Geniouskin
Geniouskin is an advanced autologous skin regeneration platform designed to rebuild living, functional, and naturally pigmented skin.
By combining the three essential skin cell types, keratinocytes, fibroblasts, and melanocytes — into a single therapeutic construct, Geniouskin aims to go beyond simple wound coverage and restore the structure, biology, and appearance of real human skin.
Watch the video learn more
Technology
Two steps. One cure.
The Process
Geniouskin’s Process AI continuously monitors cell culture conditions in real time —analyzing growth patterns, detecting contamination risks, and determining the optimal timing for each production stage — reducing variability and cutting manufacturing costs by an estimated 25–40% at scale.
AI Clinical
Geniouskin’s Clinical AI analyzes wound photography at each follow-up visit to track re-epithelialization progress, predict healing trajectory, and flag early signs of complication —giving clinicians a standardized, data-driven decision support tool that strengthens evidence
generation across every treated patient
From bench to bedside
A clear path forward from research to market launch.
Phase 0 complete
Q1–Q2 2027: Patients 2–5 treated sequentially Phase 0 cannot be rushed — we need the safety data before advancing.
Q3–Q4 2027: Phase 0 completion report. 2028 — Phase I running
Phase I completion
Q1 2028: Phase I first 6–12 patients
Q4 2028: Phase I completion.
Phase II multi-site EU 50–150 patients.
2031 — EMA submission
2033 — Commercial launch
Our Team
A highly qualified team combining clinical, scientific, and business expertise.
Professor Vincent Casoli, MD, PhD is a leading plastic and reconstructive surgeon and Professor at the University of Bordeaux, where he also headed the Plastic & Reconstructive Surgery Department at the CHU de Bordeaux.
Renowned for his expertise in complex reconstruction, burns, and microsurgery, he operates at the forefront of clinical innovation. He is the co-inventor of Geniouskin®️, a breakthrough autologous engineered skin designed to restore both function and pigmentation, bridging cutting-edge regenerative medicine with real-world surgical application.
Combining surgical excellence with translational research, Professor Casoli is a key figure shaping the future of advanced skin reconstruction and regenerative therapies.
Patrick Alexandre is a serial entrepreneur and strategic builder with cross-sector experience across the United States and Europe.
He brings to Geniouskin a proven track record in brand positioning, business development, and stakeholder orchestration, having structured and scaled ventures across multiple industries before redirecting his expertise toward deep tech and life sciences.
At Geniouskin, Patrick leads the company’s strategic development: from structuring the clinical development pathway, to building the investor narrative, managing regulatory strategy partnerships, and positioning Geniouskin as a next-generation leader in regenerative medicine.
His role bridges the scientific and industrial ambitions of the project — translating a breakthrough technology into a credible, fundable, and scalable clinical platform.
Pre-clinical validation complete.
Preclinical, murine model.
patients worldwide with chronic wounds
annual global wound care market
recurrence rate with current treatments
graft take rate in pre-clinical models
